Sign up USA
Proactive Investors - Run By Investors For Investors

GTx reveals pre-clinical success for potential SUI treatment

GTx showed it could increase pelvic floor muscle mass and ‘turn off’ genes associated with muscle degradation.
GTx reveals pre-clinical success for potential SUI treatment
GTx is evaluating an orally administered treatment for postmenopausal women

GTx Inc (NASDAQ:GTXI) has told investors it has shown that its technology can increase pelvic floor muscle mass and ‘turn off’ genes associated with muscle degradation.

A Phase 2 proof-of-concept clinical trial is currently being conducted for postmenopausal women with stress urinary incontinence (SUI), though today’s data is from a preclinical study, modelled using animals.

This study approximates the pelvic floor changes that can be associated with SUI, the company said.

Two of the company’s elective androgen receptor modulators (SARMs) - GTx-024 (enobosarm) and GTx-027 - were used in the study in a mouse model.

“These results demonstrate the ability of these SARMs to restore the pelvic floor muscles to their normal weight and provide support for a potential role of these compounds in the treatment of SUI,” said Dr Ramesh Narayanan, who is acting as consultant to GTx.

The result is being presented today in New Orleans, at a meeting of the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU).

In its ongoing Phase 2 trial, GTx is evaluating the effects of orally administered enobosarm.

Jamie_55a91591db06b.jpg


Register here to be notified of future GTXI Company articles
View full GTXI profile

GTx Timeline

Related Articles

Heart-cells.jpg
April 13 2016
Jim Phillips, Midatech’s chief executive, said Zuplenz offers relief from some of the most debilitating side-effects of common cancer treatments. Generically called ondansetron, the oral soluble film eases the problem of gritty residue, having to wear a patch and sedative side effects of dissolving tablets and injections.
shutterstock_152199281_56fd078fe84f7.jpg
March 31 2016
Amryt Pharmaceuticals is coming to the market following a reverse takeover deal with the investment firm Fastnet Equities. Here boss Joseph Wiley tells us a little bit more about the AIM newcomer.
sareum-test-tubes.png
March 10 2016
November saw the Finland-based life sciences firm list on the London Exchange, raising €14.2mln.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC